Oppenheimer notes that after a Q2 “beat-and-raise,” Blueprint Medicines (BPMC) management “implored analysts to reign-in estimates due to seasonality and other uncertainties,” and then the company just beat and raised on the Ayvakit print in Q3 for “the third consecutive time” since its label expansion into indolent mastocytosis. The firm, which says it is “beginning to believe that perhaps this whole time management’s goal has been to prevent the stock from overheating in order to make shares more attractive to a would-be buyer,” calls that a bullish signal “ahead of the next possible leg-up” from early BLU-808 data. Oppenheimer reiterates an Outperform rating and $130 price target on Blueprint shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BPMC:
- Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
- Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M
- BPMC Upcoming Earnings Report: What to Expect?
- Blueprint Medicines initiated with a Neutral at UBS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
